Citius Pharmaceuticals Raises $5 Million in Securities Offering

Citius Pharmaceuticals ( (CTXR) ) has shared an announcement.

On April 23, 2026, Citius Pharmaceuticals entered into a securities purchase agreement with institutional investors for a $5 million capital raise via a registered direct offering and concurrent private placement. The company issued 4,730,457 common shares and pre-funded warrants for 345,686 shares at around $0.985 each, alongside five-year common warrants for up to 5,076,143 shares at an exercise price of $0.86.

The gross proceeds of about $5 million, with net proceeds estimated at roughly $4.5 million after fees, are earmarked to support the commercialization of LYMPHIR and development of Citius’s pipeline, as well as general corporate purposes. The April 24, 2026 closing, arranged with H.C. Wainwright as exclusive placement agent, modestly strengthens Citius’s balance sheet while diluting equity holders, and includes a 45-day restriction on additional share or convertible security issuance, signaling near-term financing stability.

The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.

The score is held back primarily by large ongoing losses and significant cash burn, reinforced by weak technical momentum. Offsetting factors include a low-debt balance sheet and positive LYMPHIR-related corporate updates indicating early commercial traction and encouraging Phase 1 signals, but valuation support is limited given negative earnings.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a Nasdaq-listed biopharmaceutical company focused on developing and commercializing first-in-class critical care products. The company owns a majority stake in Citius Oncology and markets LYMPHIR, a targeted immunotherapy for certain relapsed or refractory CTCL, while advancing late-stage candidates Mino-Lok and CITI-002 through U.S. regulatory pathways.

Its pipeline targets serious unmet medical needs including catheter-related bloodstream infections and hemorrhoid relief, with pivotal and Phase 2b trials for Mino-Lok and Halo-Lido completed in 2023. Citius is working with the FDA on next steps for these programs as it builds out its commercial infrastructure and oncology-focused footprint.

Average Trading Volume: 600,671

Technical Sentiment Signal: Sell

Current Market Cap: $20.88M

For an in-depth examination of CTXR stock, go to TipRanks’ Overview page.